Refractory Non-Hodgkin's lymphoma Suspended Phase 2 Trials for Selumetinib (DB11689)

Also known as: Refractory Non Hodgkin Lymphoma / Refractory Non-Hodgkin Lymphoma / Refractory Non-Hodgkin Lympoma / Refractory Non-Hodgkin-Lymphoma / Non-Hodgkin's lymphoma refractory / Non-Hodgkin's lymphoma NOS refractory

IndicationStatusPhase
DBCOND0024997 (Refractory Non-Hodgkin's lymphoma)Suspended2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03213691Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)Treatment